Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC
NCT07698106
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
NOT_YET_RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
Triple-Negative Breast Cancer (TNBC)
Interventions
DRUG:
Group 1-Isunakinra
Sponsor
University Health Network, Toronto
Collaborators
[object Object]